Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

NCT06997562 | Completed

• 1 other identifier: 20250430007
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Conditions

Greater Occipital Nerve Block; Sphenopalatine Ganglion Block; Episodic Migraine

Outcome Measures

Primary Outcomes (1)

• Degree of headache intensity

  Reduction in headache intensity will be recorded using numeric rating scale (NRS). Each patient will be instructed about pain assessment with NRS score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").

  3 months post-procedure

Secondary Outcomes (3)

• Migraine disability assessment score

  3 months post-procedure

• Headache duration

  3 months post-procedure

• Headache frequency

  3 months post-procedure

Study Arms (2)

Greater occipital nerve blockade group

EXPERIMENTAL

Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.

Other: Greater occipital nerve blockade

Sphenopalatine ganglion blockade group

EXPERIMENTAL

Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.

Other: Sphenopalatine ganglion blockade

Interventions

Greater occipital nerve blockade OTHER

Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.

Greater occipital nerve blockade group

Sphenopalatine ganglion blockade OTHER

Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.

Sphenopalatine ganglion blockade group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18-65 years.
• Both sexes.
• Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
• Failure to achieve adequate relief with at least one prophylactic migraine treatment.

You may not qualify if:

• Chronic migraine (≥15 headache days per month).
• History of nerve blocks within the last 6 months.
• Known allergy to anesthetic agents.
• Pregnancy or lactation.
• Active psychiatric conditions affecting compliance.

Sponsors & Collaborators

• New Valley University: lead

Study Sites (1)

New Valley University

New Valley, New Valley Governorate, 72511, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesia and Intensive Care, Faculty of Medicine, New Valley University, Egypt.

Study Record Dates

• First Submitted: May 21, 2025
• First Posted: May 30, 2025
• Study Start: May 1, 2024
• Primary Completion: May 3, 2025
• Study Completion: May 3, 2025
• Last Updated: May 30, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)